Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527046 · ClinicalTrials.gov registry record · Phase 2
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT00527046 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 396 participants.
The verdict
NCT00527046, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.
Interventions
- DRUG CP-424,391
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 1999-12 |
| Est. Completion | 2001-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527046
The ClinicalTrials.gov registry entry for NCT00527046 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-424,391 is the first listed.
NCT00527046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527046 about?
NCT00527046 is a clinical study titled "Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults". A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.
What is the current status of trial NCT00527046?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 1999-12. Estimated completion is 2001-10.
What interventions are being tested in trial NCT00527046?
The interventions under investigation include: CP-424,391 (DRUG).
Who is sponsoring clinical trial NCT00527046?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.